In This Article:
Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities
ATLANTA, GA - April 22, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced the appointment of Senthil Ranganathan, Ph.D. as Vice President, Technical Development and CMC Operations. Dr. Ranganathan brings over 20 years of experience in biologics development to commercialization across vaccines, cell and gene therapies, monoclonal antibodies, and viral vector products.
This appointment comes at a pivotal time for GeoVax as it advances a comprehensive portfolio of infectious disease vaccines and cancer therapies, positioning the Company to address significant unmet medical needs, contributing to biodefense readiness, and improving vaccine and therapeutic equity through innovation and onshoring.
David Dodd, Chairman & CEO of GeoVax, stated: "We are delighted to welcome Senthil to GeoVax. His track record and expertise in a breadth of biologics development and preparation for registration and subsequent commercialization will support and enhance our progress as we proceed towards the authorization and subsequent commercialization stages for our exciting development portfolio."
Dr. Ranganathan has held senior leadership roles across industry-leading biopharmaceutical companies, most recently serving as Head of Process Development CMC for the Boston site of National Resilience. He previously led global CMC and manufacturing operations at Athersys, Zymeworks, and Alder Biopharmaceuticals (acquired by Lundbeck Biopharmaceuticals). His career has spanned the development and validation of cell and gene therapies, vaccines, bispecific antibodies, and other biologicsfrom pre-IND through licensure and commercialization.
He holds a Ph.D. in Biochemistry from Loyola University Chicago and has authored numerous regulatory submissions and publications in support of breakthrough vaccines, biologics, and therapies.
"I am honored to join GeoVax during such a critical stage of the Company's growth and development," said Dr. Ranganathan. "I look forward to working with the outstanding GeoVax team as we develop and execute the roadmap that will bring the GeoVax portfolio to benefit patients and communities worldwide."
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.